Results 151 to 160 of about 5,637,645 (256)
Applications of circulating tumor cells in esophageal cancer detection and treatment. [PDF]
Long F +5 more
europepmc +1 more source
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett +7 more
wiley +1 more source
Slug-positive circulating tumor cells in mesenchymal malignancies: what remains to validate. [PDF]
Gholami AA, Mirzaeva D, Soleyeva S.
europepmc +1 more source
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave +8 more
wiley +1 more source
Circulating tumor cells as biomarkers in melanoma: techniques, challenges, and clinical applications. [PDF]
Broseghini E +7 more
europepmc +1 more source
How is Nanoarchitectonics Shaping Extracellular Vesicle Research?
The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake +5 more
wiley +1 more source
Integrated Molecular and Phenotypic Profiling of Circulating Tumor Cells in Gastric Cancer: A Translational Perspective. [PDF]
Eskandarion MR +9 more
europepmc +1 more source
Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans +7 more
wiley +1 more source
Interactions Between Circulating Tumor Cells and the Immune System in Colorectal Cancer: Friends or Foes? [PDF]
De Meo M, Nicolazzo C.
europepmc +1 more source

